BIOS Stock Overview
BioSenic S.A., a biotech company, focuses on developing clinical assets.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioSenic S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.02 |
| 52 Week High | €0.19 |
| 52 Week Low | €0.012 |
| Beta | 0 |
| 1 Month Change | -8.11% |
| 3 Month Change | -54.67% |
| 1 Year Change | -83.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOS | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | -16.7% | -2.6% | -0.7% |
| 1Y | -83.7% | -12.3% | -5.4% |
Return vs Industry: BIOS underperformed the Belgian Biotechs industry which returned -12.4% over the past year.
Return vs Market: BIOS underperformed the Belgian Market which returned -6.4% over the past year.
Price Volatility
| BIOS volatility | |
|---|---|
| BIOS Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.9% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: BIOS's share price has been volatile over the past 3 months.
Volatility Over Time: BIOS's weekly volatility has decreased from 26% to 11% over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | François Rieger | www.biosenic.com |
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.
BioSenic S.A. Fundamentals Summary
| BIOS fundamental statistics | |
|---|---|
| Market cap | €3.74m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BIOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOS income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BIOS perform over the long term?
See historical performance and comparison